Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Jayachandran

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 27, 2022
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical TrialsMaria Garcia-Cremades, Katarina Vučićević, Craig W Hendrix, et al.
Oncogene|October 1, 2022
Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatmentFrancesca Battaglin, Priya Jayachandran, Carly Strelez, et al.
International Journal of Molecular Sciences|March 27, 2025
Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal CancerPooja Mittal, Francesca Battaglin, Yan Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trialsJingyuan Wang, Yi Xiao, Fotios Loupakis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 7, 2012
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic featuresDaniel T Chang, Rish K Pai, Lisa A Rybicki, et al.
Oncogene|January 17, 2023
Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directionsPriya Jayachandran, Francesca Battaglin, Carly Strelez, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2021
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant WomenJyoti S Mathad, Rada Savic, Paula Britto, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 27, 2022
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical TrialsMaria Garcia-Cremades, Katarina Vučićević, Craig W Hendrix, et al.
Oncogene|October 1, 2022
Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatmentFrancesca Battaglin, Priya Jayachandran, Carly Strelez, et al.
International Journal of Molecular Sciences|March 27, 2025
Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal CancerPooja Mittal, Francesca Battaglin, Yan Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trialsJingyuan Wang, Yi Xiao, Fotios Loupakis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 7, 2012
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic featuresDaniel T Chang, Rish K Pai, Lisa A Rybicki, et al.
Oncogene|January 17, 2023
Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directionsPriya Jayachandran, Francesca Battaglin, Carly Strelez, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2021
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant WomenJyoti S Mathad, Rada Savic, Paula Britto, et al.
Pageof 6